Actualités

Halozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company’s annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]

Halozyme Therapeutics recently announced that Darren Snellgrove, a veteran finance leader with more than 30 years of biopharma experience including senior roles at Johnson & Johnson, will become its Chief Financial Officer on June 8, 2026, overseeing financial operations, capital allocation, corporate development, and investor relations. Snellgrove’s background combining investor relations leadership and oversight of a Johnson & Johnson pharmaceuticals business generating over...

Halozyme Therapeutics has seen its modelled Fair Value price target updated to $85.78 from $84.89, reflecting a modest recalibration in the latest assumptions. Analysts linking this change to current research point to royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms as key factors shaping views on valuation and execution risk. As you read on, you will see how these moving pieces feed into the evolving narrative around Halozyme and what to watch next in the...

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

If you are wondering whether Halozyme Therapeutics at around US$68.41 is offering good value or asking too much, you are not alone. The share price performance has been mixed recently, with a 1.6% return over 7 days, 7.9% over 30 days, a 2.7% decline year to date, and a 17.5% return over the past year, alongside a 103.8% return over 3 years and 33.8% over 5 years. Recent coverage has focused on how Halozyme Therapeutics fits into broader biotech themes and how its partnerships and product...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. According to the collaboration, Vertex has licensed Halozyme Therapeutics’ (NASDAQ:HALO) Hypercon™ technology […]

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.